Taiwan Liposome Company PEG Ratio

Taiwan Liposome Company's peg ratio stands at 13.15. That is above the Healthcare sector average of 1.26. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Taiwan Liposome Company sits higher the Healthcare benchmark (1.26) with a PEG ratio of 13.15. That is roughly 946.3% above the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

Whether 13.15 is attractive depends on Taiwan Liposome Company's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.

The history chart shows how Taiwan Liposome Company's PEG ratio evolved across reporting periods, while the comparison chart places TLC next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, PEG ratio is commonly used to spot outliers. Taiwan Liposome Company's reading of 13.15 (sector avg 1.26) is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.